Trial Profile

Satoreotide Theranostic Pilot study in Extensive Stage in Small Cell Lung Cancer (ES-SCLC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium 177 satoreotide tetraxetan (Primary) ; SS-0120 (Primary)
Indications Small cell lung cancer
Focus Adverse reactions
Acronyms LuSato-1
Sponsors Ariceum Therapeutics

Most Recent Events

12 Sep 2023 New trial record
07 Sep 2023 According to an Ariceum Therapeutics media release, An Abstract on the LuSato-1 study will be presented at the European Association of Nuclear Medicine Congress 2023 (EANM 2023).
07 Sep 2023 According to an Ariceum Therapeutics media release, first patient has been dosed in this study at the Murdoch University Health Center in Perth, Australia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com